Aldurazyme
Named-patient access overview. Aldurazyme is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Aldurazyme (laronidase) is a recombinant human alpha-L-iduronidase enzyme replacement therapy co-developed by Sanofi-Genzyme and BioMarin. The US Food and Drug Administration approved Aldurazyme in April 2003 for the long-term treatment of patients with mucopolysaccharidosis type I (MPS I), specifically the Hurler and Hurler-Scheie forms, and the Scheie form with moderate-to-severe symptoms. The drug is administered as a weekly intravenous infusion at 0.58 mg/kg over approximately 3 to 4 hours, with pre-medication for infusion-associated reactions. Treatment is delivered in a hospital or specialised infusion centre under the supervision of a metabolic specialist. Reserved for you.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Aldurazyme
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Aldurazyme is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Aldurazyme in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Aldurazyme
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.